Monte Rosa Therapeutics Reports Q4 and Full-Year 2025 Financial Results and Major Clinical Progress

Key Highlights from the Report

• Positive Interim Phase 1 Results for NEK7-directed MGD MRT-8102: Profound reductions in CRP (C-reactive protein) in subjects with elevated cardiovascular disease (CVD) risk, with an anticipated Phase 2 readout for the GFORCE-1 trial in H2 2026.
• Favorable Safety Data for MRT-8102: Newly announced unblinded safety data from single and multiple ascending dose cohorts reinforce a strong safety/tolerability profile and a wide therapeutic window.
• Multiple Upcoming Phase 2 Studies: Plans to initiate Phase 2 studies of MRT-8102 in patients with elevated CVD risk (H2 2026), gout flares (Q4 2026/Q1 2027), and moderate to severe hidradenitis suppurativa (H1 2027).
• Strong Interim Data for MRT-2359 in mCRPC: 100% PSA response rate in metastatic castration-resistant prostate cancer (mCRPC) patients with AR mutations when combined with enzalutamide. A Phase 2 study combining MRT-2359 and apalutamide is set to begin in Q3 2026.
• VAV1-directed MGD MRT-6160 Moving Forward: Novartis is expected to initiate multiple Phase 2 studies in immune-mediated diseases in 2026. Monte Rosa stands to receive up to \$2.1 billion in milestones and royalties from this collaboration.
• Significant Strengthening of Balance Sheet: Raised \$345 million in an upsized follow-on financing in January 2026, extending cash runway into 2029.
• Expanded Partnerships: New collaboration agreement with Novartis (up to \$5.7 billion in potential value) and milestone achievement with Roche.

Detailed Business Update

Clinical Programs

MRT-8102 (NEK7-directed MGD):

• Phase 1 Results: Demonstrated rapid and durable reductions in systemic inflammation. After four weeks, CRP levels dropped by 85%, and 94% of participants reduced CRP below 2 mg/L—a threshold linked to reduced CVD risk.
• Safety: Across 88 participants, there were no serious adverse events or Grade 3+ adverse events. Headache was the most common AE (9% in both drug and placebo groups). The safety profile is comparable to or better than biologic therapies.
• Preclinical Support: In a primate model, NEK7 degradation led to an 8% reduction in body weight; combined with semaglutide, weight loss exceeded 23%. There was significant preferential reduction in central abdominal fat—a key marker for metabolic risk.
• Upcoming Trials:
  • GFORCE-1: Ongoing, with expanded dosing; H2 2026 readout expected.
  • GFORCE-2: To start H2 2026 for CVD risk patients with chronic kidney disease and elevated CRP.
  • GFORCE-3: Gout flares, Q4 2026/Q1 2027.
  • GFORCE-4: Moderate to severe hidradenitis suppurativa, H1 2027.

MRT-2359 (GSPT1-directed MGD for mCRPC):

• Phase 1/2 Interim Data: In combination with enzalutamide, 5/5 patients with AR mutations had PSA response and 100% disease control rate (2 partial responses, 3 stable disease). Overall disease control rate was 67% in 15 evaluable patients.
• Safety: Well-tolerated, mostly Grade 1-2 AEs, no discontinuations due to AEs.
• Next Steps: Phase 2 study (MODeFIRe-1) with up to 25 patients to assess efficacy in combination with apalutamide, expected to initiate Q3 2026. Johnson & Johnson will supply apalutamide for the study.

MRT-6160 (VAV1-directed MGD for immune-mediated conditions):

• Advancing to Phase 2: Novartis will begin multiple Phase 2 studies in 2026. Monte Rosa is eligible for up to \$2.1 billion in milestones and royalties, sharing U.S. profits/losses 30%/70% with Novartis.
• Preclinical Data: Demonstrated broad activity in autoimmune disease models, reducing autoantibodies and organ pathology.

Pipeline Expansion:

• Continued progress on cyclin E1 (CCNE1) and CDK2-directed MGDs for solid tumors, with an IND submission planned for 2026.

Corporate and Financials

• Public Offering: Closed an upsized offering in January 2026, raising gross proceeds of \$345 million, with net proceeds of \$323.8 million.
• Cash Position: As of December 31, 2025, cash and equivalents totaled \$382.1 million. With the recent offering, cash runway is extended into 2029—fully funding planned clinical operations through multiple anticipated data readouts.
• Collaboration Revenue: \$2.8 million in Q4 2025 (\$123.7 million for full year), compared to \$60.6 million in Q4 2024 (\$75.6 million full year 2024). Decrease reflects timing of milestone payments.
• R&D Expenses: \$42 million for Q4 2025, \$141.5 million for the year, up from \$38.9 million and \$121.6 million, respectively, due to increased clinical and preclinical program activity.
• G&A Expenses: \$10.5 million in Q4, \$36.4 million for the year, up slightly, reflecting increased headcount and stock-based compensation.
• Net Loss: Q4 2025 net loss of \$46.1 million, full year net loss \$38.6 million (improved from \$72.7 million loss in 2024).
• New Partnerships: September 2025: Second collaboration with Novartis for novel degraders in immune-mediated diseases (up to \$5.7 billion total potential deal value). December 2025: \$7 million milestone from Roche.
• Leadership Promotions: Magnus Walter, DPhil, promoted to Chief Technology Officer; Andrew Funderburk to Chief Investor Relations and Strategy Officer.

Potential Price-Sensitive Items for Shareholders

• Clinical Progress: Multiple upcoming trial readouts and new Phase 2 trial initiations in high-value indications (CVD, autoimmune, oncology) are potential value inflection points that could drive share price.
• Financial Strength: The recent \$345 million raise, extending cash runway into 2029, ensures the company is well-funded to deliver on its pipeline without near-term dilution risk.
• Partnerships: Expansion of collaborations with Novartis (up to \$5.7 billion total potential value) and Roche milestones provide significant non-dilutive capital and validation from major pharma partners.
• Positive Data: The 100% PSA response rate in mCRPC with AR mutations, durable CRP reductions in CVD risk patients, and favorable safety profile for MRT-8102 are all strongly supportive of future value creation.

Upcoming Milestones

• Readout of MRT-8102 GFORCE-1 CVD risk study (H2 2026)
• Initiation of multiple Phase 2 studies for MRT-8102 (H2 2026–H1 2027)
• MODeFIRe-1 Phase 2 study for MRT-2359 in mCRPC (Q3 2026)
• IND submission for cyclin E1-directed MGD (2026)
• Multiple Phase 2 studies for MRT-6160 by Novartis (2026)

Disclaimer: This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated. Investors should review the company’s filings with the SEC and consult their own advisors before making investment decisions.

View Monte Rosa Therapeutics, Inc. Historical chart here